InspireMD, Inc. (NSPR) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for InspireMD, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, InspireMD, Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does InspireMD, Inc. actually do?
Answer:
InspireMD is a medical device company focused on developing and commercializing products for carotid artery disease and other vascular conditions. Its core technology is the proprietary CGuard carotid stent, which integrates a nitinol stent with a MicroNet mesh sleeve designed to prevent embolic events during and after stenting procedures. The company markets CGuard EPS in over 30 countries outside the U.S. through distributors, and recently launched CGuard Prime in the U.S. following FDA premarket approval in June 2025. InspireMD is also developing the SwitchGuard neuroprotection system for use in Transcarotid Artery Revascularization (TCAR) procedures.
Question:
What are InspireMD, Inc.'s revenue drivers?
Answer:
Revenue is driven by sales of its CGuard EPS product through international distributors and the recent launch of CGuard Prime in the United States via a direct salesforce.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required